Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Other hematologic neoplasm 1Myeloid 1Lymphoid 1

Conditions

Precursor Cell Lymphoblastic Leukemia-Lymphoma 1Myelodysplastic Syndromes 1Leukemia, Myeloid, Acute 1

Interventions

Specimen Handling 49pembrolizumab 44Magnetic Resonance Spectroscopy 37Biopsy 35Cyclophosphamide 33fludarabine 28Cetuximab 20Cisplatin 19Carboplatin 19Bevacizumab 16atezolizumab 15Radiation 15venetoclax 14Fluorouracil 14fludarabine phosphate 13Radiotherapy 13Leucovorin 13Nivolumab 12Gemcitabine 12Pemetrexed 11Oxaliplatin 11Cytarabine 11Irinotecan 10130-nm albumin-bound paclitaxel 10Prednisone 9Paclitaxel 9Immunoglobulin G 9Fulvestrant 9durvalumab 8Temozolomide 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1 × Lymphatic Irradiation × 30 days × Clear all
NCT06287944 2026-05-18

225Ac-DOTA-Anti-CD38 Daratumumab Monoclonal Antibody With Fludarabine, Melphalan and Total Marrow and Lymphoid Irradiation as Conditioning Treatment for Donor Stem Cell Transplant in Patients With High-Risk Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia and Myelodysplastic Syndrome

City of Hope Medical Center

Phase 1 Recruiting
15 enrolled
LymphoidMyeloidOther hematologic neoplasm

Myelodysplastic Syndromes, Leukemia, Myeloid, Acute, Precursor Cell Lymphoblastic Leukemia-Lymphoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡